中国药物警戒 ›› 2011, Vol. 8 ›› Issue (9): 521-523.

• 基础及临床研究 • 上一篇    下一篇

阿莫西林/克拉维酸钾联合左氧氟沙星治疗耐多药肺结核临床疗效分析

王晓, 刘幸, 王璐   

  1. 云南省昆明市第三人民医院,云南 昆明 650041
  • 收稿日期:2011-01-04 出版日期:2011-09-10 发布日期:2015-07-30
  • 作者简介:王晓,女,主管药师,临床药学。

Clinical Efficacy Analysis of Amoxicillin/clavulanic Potassium Combined Levofloxacin in the treatment of multi-drug resistant tuberculosis (MDR-TB)

WANG Xiao, LIU Xing, WANG Lu   

  1. The Third People's Hospital of Kunming, Yunnan Kunming 650041, China
  • Received:2011-01-04 Online:2011-09-10 Published:2015-07-30

PDF (PC)

269

摘要： 目的 观察并评价阿莫西林/克拉维酸钾联合左氧氟沙星在耐多药肺结核（MDR-TB）治疗中的效果。方法 将101 例复治涂阳耐多药肺结核患者随机分为治疗组52例和对照组49 例;化疗方案：治疗组以阿莫西林/克拉维酸钾、左氧氟沙星为主,联合吡嗪酰胺、盐酸乙胺丁醇、对氨基水杨酸异烟肼、利福喷叮;对照组以左氧氟沙星为主,联合用药同治疗组;所有病例疗程均为12个月。结果 治疗中途因药物不良反应终止治疗5例,治疗组实际完成50例,对照组实际完成46例。至疗程结束,治疗组痰菌阴转率为78.0%,对照组痰菌阴转率为56.5%,痰菌阴转率治疗组明显高于对照组（P <0.05）;治疗组病灶吸收有效率为78.0%,空洞闭合有效率为82.0%,病灶吸收有效率及空洞闭合有效率治疗组均明显高于对照组（P <0.05）。结论 阿莫西林/克拉维酸钾联合左氧氟沙星方案治疗耐多药肺结核有助于痰菌阴转和病变吸收好转,药品不良反应低,值得在临床上推广应用。

关键词: 阿莫西林/克拉维酸钾, 左氧氟沙星, 耐多药肺结核

Abstract: Objective To observe and evaluate the clinical effect of amoxicillin/clavulanate potassium combined levofloxacin in multi-drug resistant tuberculosis(MDR-TB). Methods 101 cases of retreatment smear-positive MDR-TB patients were randomly divided into treatment group(52 patients) and control group(49 patients); chemotherapy: the treatment group based on amoxicillin/clavulanate potassium and levofloxacin, associated with pyrazinamide, ethambutol, aminosalicylic acid isoniazid and rifampicin spray bite; The control group based on levofloxacin, combination therapy is same with the treatment group; The treatment course of all cases is 12 months. Results 5 patients were terminated because of adverse drug reactions In the course of treatment, the treatment group actually completed 50 patients, the control group actually completed 46 patients. To the end of treatment, sputum conversion rate of treatment group and control group Separately was 78.0% and 56.5%, sputum conversion rate in the treated group was significantly higher than the control group(P <0.05); foci effective rate of treatment group was 78.0%, cavity closure rate was 82.0%, foci effective rate and cavity closure rate in treatment group were significantly higher than the control group(P <0.05). Conclusion amoxicillin/clavulanate potassium combined levofloxacin in the treatment of MDR-TB was contribute to sputum conversion and Absorption of the lesion, adverse drug reactions was low, worthy of clinical application.

Key words: amoxicillin/clavulanic potassium, levofloxacin, multi-drug resistant tuberculosis

中图分类号: